The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

NCT04134091 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG: LPCN 1144 Formulation A
DRUG: LPCN 1144 Formulation B
DRUG: Placebo

Sponsor

Lipocine Inc.